Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Helena Jernberg Wiklund is active.

Publication


Featured researches published by Helena Jernberg Wiklund.


BMC Cancer | 2012

Stat1 activation attenuates IL-6 induced Stat3 activity but does not alter apoptosis sensitivity in multiple myeloma

Lina Y. Dimberg; Anna Dimberg; Karolina Ivarsson; Mårten Fryknäs; Linda Rickardson; Gerard Tobin; Simon Ekman; Rolf Larsson; Urban Gullberg; Kenneth Nilsson; Fredrik Öberg; Helena Jernberg Wiklund

BackgroundMultiple myeloma (MM) is at present an incurable malignancy, characterized by apoptosis-resistant tumor cells. Interferon (IFN) treatment sensitizes MM cells to Fas-induced apoptosis and is associated with an increased activation of Signal transducer and activator of transcription (Stat)1. The role of Stat1 in MM has not been elucidated, but Stat1 has in several studies been ascribed a pro-apoptotic role. Conversely, IL-6 induction of Stat3 is known to confer resistance to apoptosis in MM.MethodsTo delineate the role of Stat1 in IFN mediated sensitization to apoptosis, sub-lines of the U-266-1970 MM cell line with a stable expression of the active mutant Stat1C were utilized. The influence of Stat1C constitutive transcriptional activation on endogenous Stat3 expression and activation, and the expression of apoptosis-related genes were analyzed. To determine whether Stat1 alone would be an important determinant in sensitizing MM cells to apoptosis, the U-266-1970-Stat1C cell line and control cells were exposed to high throughput compound screening (HTS).ResultsTo explore the role of Stat1 in IFN mediated apoptosis sensitization of MM, we established sublines of the MM cell line U-266-1970 constitutively expressing the active mutant Stat1C. We found that constitutive nuclear localization and transcriptional activity of Stat1 was associated with an attenuation of IL-6-induced Stat3 activation and up-regulation of mRNA for the pro-apoptotic Bcl-2 protein family genes Harakiri, the short form of Mcl-1 and Noxa. However, Stat1 activation alone was not sufficient to sensitize cells to Fas-induced apoptosis. In a screening of > 3000 compounds including bortezomib, dexamethasone, etoposide, suberoylanilide hydroxamic acid (SAHA), geldanamycin (17-AAG), doxorubicin and thalidomide, we found that the drug response and IC50 in cells constitutively expressing active Stat1 was mainly unaltered.ConclusionWe conclude that Stat1 alters IL-6 induced Stat3 activity and the expression of pro-apoptotic genes. However, this shift alone is not sufficient to alter apoptosis sensitivity in MM cells, suggesting that Stat1 independent pathways are operative in IFN mediated apoptosis sensitization.


Cell Cycle | 2016

Growth signals employ CGGBP1 to suppress transcription of Alu-SINEs

Prasoon Agarwal; Stefan Enroth; Martin Teichmann; Helena Jernberg Wiklund; Arian Smit; Bengt Westermark; Umashankar Singh

ABSTRACT CGGBP1 (CGG triplet repeat-binding protein 1) regulates cell proliferation, stress response, cytokinesis, telomeric integrity and transcription. It could affect these processes by modulating target gene expression under different conditions. Identification of CGGBP1-target genes and their regulation could reveal how a transcription regulator affects such diverse cellular processes. Here we describe the mechanisms of differential gene expression regulation by CGGBP1 in quiescent or growing cells. By studying global gene expression patterns and genome-wide DNA-binding patterns of CGGBP1, we show that a possible mechanism through which it affects the expression of RNA Pol II-transcribed genes in trans depends on Alu RNA. We also show that it regulates Alu transcription in cis by binding to Alu promoter. Our results also indicate that potential phosphorylation of CGGBP1 upon growth stimulation facilitates its nuclear retention, Alu-binding and dislodging of RNA Pol III therefrom. These findings provide insights into how Alu transcription is regulated in response to growth signals.


BMC Genomics | 2015

CGGBP1 mitigates cytosine methylation at repetitive DNA sequences

Prasoon Agarwal; Paul Collier; Markus Hsi-Yang Fritz; Vladimir Benes; Helena Jernberg Wiklund; Bengt Westermark; Umashankar Singh

BackgroundCGGBP1 is a repetitive DNA-binding transcription regulator with target sites at CpG-rich sequences such as CGG repeats and Alu-SINEs and L1-LINEs. The role of CGGBP1 as a possible mediator of CpG methylation however remains unknown. At CpG-rich sequences cytosine methylation is a major mechanism of transcriptional repression. Concordantly, gene-rich regions typically carry lower levels of CpG methylation than the repetitive elements. It is well known that at interspersed repeats Alu-SINEs and L1-LINEs high levels of CpG methylation constitute a transcriptional silencing and retrotransposon inactivating mechanism.ResultsHere, we have studied genome-wide CpG methylation with or without CGGBP1-depletion. By high throughput sequencing of bisulfite-treated genomic DNA we have identified CGGBP1 to be a negative regulator of CpG methylation at repetitive DNA sequences. In addition, we have studied CpG methylation alterations on Alu and L1 retrotransposons in CGGBP1-depleted cells using a novel bisulfite-treatment and high throughput sequencing approach.ConclusionsThe results clearly show that CGGBP1 is a possible bidirectional regulator of CpG methylation at Alus, and acts as a repressor of methylation at L1 retrotransposons.


Blood | 1996

Insulin-like growth factor I is a growth and survival factor in human multiple myeloma cell lines

Patrik Georgii-Hemming; Helena Jernberg Wiklund; Ljunggren O; Kenneth Nilsson


Blood | 1999

The Somatostatin Analog Octreotide Inhibits Growth of Interleukin-6 (IL-6)–Dependent and IL-6–Independent Human Multiple Myeloma Cell Lines

Patrik Georgii-Hemming; Thomas Strömberg; Eva Tiensuu Janson; Mats Stridsberg; Helena Jernberg Wiklund; Kenneth Nilsson


Blood | 2005

Ectopic and IFN-induced expression of Fas overcomes resistance to Fas-mediated apoptosis in multiple myeloma cells

Lina Y. Dimberg; Anna Dimberg; Karolina Ivarsson; Thomas Strömberg; Anders Österborg; Kenneth Nilsson; Fredrik Öberg; Helena Jernberg Wiklund


Oncotarget | 2015

Increased resistance to proteasome inhibitors in multiple myeloma mediated by cIAP2 - implications for a combinatorial treatment

Charlotte Fristedt Duvefelt; Susanne Lub; Prasoon Agarwal; Linda Arngården; Anna Hammarberg; Ken Maes; Els Van Valckenborgh; Karin Vanderkerken; Helena Jernberg Wiklund


International Journal of Cancer | 1995

A novel human B-cell line (U-2904) bearing t(8;14) and t(14;18) translocations.

Clara Sambade; Jan Sällström; Helena Jernberg Wiklund; Gunilla Enblad; Syrje Kivi; Fátima Gärtner; Lore Zech; Bengt Glimelius; Christer Sundström


Archive | 2000

Plasma Cell and Myeloma Cell Lines

Helena Jernberg Wiklund; Kenneth Nilsson


Blood | 2014

Recurrent Mutations within the Nfkbie gene : A Novel Mechanism for NF-kappa B Deregulation in Aggressive Chronic Lymphocytic Leukemia

Larry Mansouri; Lesley-Ann Sutton; Viktor Ljungström; Sina Bondza; Linda Arngården; Sujata Bhoi; Jimmy Larsson; Diego Cortese; Antonia Kalushkova; Rebeqa Gunnarsson; Emma Young; Elin Falk-Sörqvist; Karla Plevová; Alice F. Muggen; Xiao-Jie Yan; Birgitta Sander; Gunilla Enblad; Karin E. Smedby; Gunnar Juliusson; Chrysoula Belessi; Nicholas Chiorazzi; Jonathan C. Strefford; Anton W. Langerak; Šárka Pospíšilová; Frederic Davi; Mats Hellström; Helena Jernberg Wiklund; Paolo Ghia; Ola Söderberg; Kostas Stamatopoulos

Collaboration


Dive into the Helena Jernberg Wiklund's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Ken Maes

Vrije Universiteit Brussel

View shared research outputs
Researchain Logo
Decentralizing Knowledge